603538.SS SHH
Ningbo Menovo Pharmaceutical Co., Ltd.
1W: -0.8%
1M: +8.1%
3M: +2.1%
YTD: +33.6%
1Y: +9.7%
3Y: +55.8%
5Y: -7.1%
¥28.59 ($4.26)
+2.60 (+10.00%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$4.7B
+5.1% ▲
5Y CAGR: +12.2%
Total Liabilities
$2.4B
+5.4% ▲
5Y CAGR: +17.7%
Shareholders Equity
$2.2B
+4.6% ▲
5Y CAGR: +10.0%
Cash & Investments
$740M
+2.1% ▲
5Y CAGR: +10.8%
Total Debt
$1.1B
-12.2% ▼
5Y CAGR: +13.9%
Net Debt
$558M
-29.4% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $236M | $422M | $792M | $456M | $585M |
| Short-Term Investments | $133M | $371M | $217M | $269M | $154M |
| Cash & ST Investments | $369M | $793M | $1.0B | $725M | $740M |
| Net Receivables | $165M | $239M | $216M | $321M | $361M |
| Inventory | $455M | $580M | $594M | $613M | $774M |
| Other Current Assets | $117M | $107M | $103M | $101M | $83M |
| Total Current Assets | $1.1B | $1.7B | $1.9B | $1.8B | $2.0B |
| Property, Plant & Equip. | $1.1B | $1.6B | $1.8B | $1.9B | $1.9B |
| Goodwill & Intangibles | $247M | $224M | $172M | $206M | $235M |
| Long-Term Investments | $275M | -$52M | $83M | $47M | $173M |
| Other Non-Current Assets | $215M | $478M | $345M | $468M | $343M |
| Total Non-Current Assets | $1.9B | $2.3B | $2.5B | $2.7B | $2.7B |
| Total Assets | $3.1B | $4.0B | $4.4B | $4.4B | $4.7B |
| — Liabilities — | |||||
| Accounts Payable | $372M | $389M | $208M | $391M | $634M |
| Short-Term Debt | $692M | $426M | $497M | $543M | $479M |
| Deferred Revenue | $88M | $249M | $195M | $153M | $0 |
| Other Current Liabilities | $37M | $164M | $264M | $227M | $352M |
| Total Current Liabilities | $1.1B | $1.1B | $1.4B | $1.4B | $1.6B |
| Long-Term Debt | $109M | $727M | $675M | $744M | $652M |
| Other Non-Current Liab. | $39M | $5M | -$66M | $86M | $5M |
| Total Non-Current Liabilities | $188M | $876M | $884M | $860M | $774M |
| Total Liabilities | $1.3B | $2.0B | $2.2B | $2.2B | $2.4B |
| — Equity — | |||||
| Common Stock | $150M | $151M | $213M | $213M | $219M |
| Retained Earnings | $812M | $937M | $1.2B | $1.2B | $1.3B |
| Accumulated OCI | $34M | $78M | $101M | $0 | $0 |
| Total Stockholders Equity | $1.6B | $1.8B | $2.1B | $2.1B | $2.2B |
| Total Liabilities & Equity | $3.1B | $4.0B | $4.4B | $4.4B | $4.7B |
| — Key Metrics — | |||||
| Total Debt | $757M | $1.3B | $1.2B | $1.3B | $1.1B |
| Net Debt | $522M | $839M | $411M | $790M | $558M |
| Total Investments | $409M | $320M | $300M | $315M | $327M |